The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation

Frontiers in Pharmacology · 9 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This narrative review summarizes evidence that long non-coding RNAs regulate metabolic pathways—including glucose, lipid, amino acid metabolism, and mitochondrial dynamics—in renal cell carcinoma progression, acting primarily through the lncRNA-miRNA-mRNA axis. The authors identify lncRNAs as potential diagnostic biomarkers and therapeutic targets for RCC via metabolic modulation.

Full summary

807 CHARS

This narrative review synthesizes published literature on the role of long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC) progression through metabolic regulation. The authors describe how RCC satisfies proliferative demands via aerobic glycolysis and summarize lncRNA involvement in glucose metabolism, lipid metabolism, amino acid metabolism, and mitochondrial dynamics. LncRNAs are reported to modulate metabolism-related genes such as c-MYC, ASS1, and mTORC1, primarily through competitive endogenous RNA (ceRNA) mechanisms binding to miRNAs. The authors note that relatively few studies have specifically investigated lncRNA-mediated RCC progression through metabolic pathways. They also identify unresolved issues including the obesity paradox and targeting effects of SCD1 inhibitors in RCC.

STUDY TYPE

narrative_review

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10034124

The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation

Frontiers in Pharmacology

READ THE FULL PAPER

ABSTRACT

Renal cell carcinoma (RCC) is the most frequent renal malignancy in the world, and its incidence is increasing year by year. RCC is a well-known drug resistant tumor, and the treatment methods are limited. Most patients with RCC are discovered at the advanced stage, and thus have poor prognosis even after treatment. Therefore, it is very urgent to find new markers for the diagnosis and treatment of RCC. Accumulating evidence shows that lncRNAs participate in the occurrence and progression of RCC, which is achieved by the lncRNA-miRNA-mRNA axis. It is widely known that metabolic defect is an essential pathogenesis in RCC. As is the case with other tumors, RCC can satisfy the demands of cancerous cells for uncontrolled proliferation through aerobic glycolysis. However, whether lncRNAs can modulate RCC progression through metabolic pathway is still not clarified. Taken together, this review mainly summarized the metabolic regulatory mechanisms of lncRNAs in RCC progression, especially their roles in glucose metabolism, lipid metabolism, amino acid metabolism and mitochondrial dynamics, as well as the clinical applications of lncRNAs via targeting metabolism in RCC therapy. It will provide the new targets and approaches for early clinical diagnosis, treatment and prognosis of RCC.

CITATION EXPORT

Xingyu Gao, Haiying Zhang, Chang Zhang et al.. The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation. Frontiers in Pharmacology. (2023). https://doi.org/10.3389/fphar.2023.1122065

AUTHORS

9 · 3 CENTRES

Xingyu Gao, Haiying Zhang, Chang Zhang, Minghe Li, Xiao Yu, Yanan Sun, Yingai Shi, Hongxia Zhang, Xu He

1 The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun, China
2 Reproductive Medicine Center, China-Japan Union Hospital, Jilin University, Changchun, China
3 Department of Rehabilitation Medicine, China-Japan Union Hospital, Jilin University, Changchun, China